Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study

Survival of patients with completely resected non-small-cell lung cancer (NSCLC) is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established. This phase III study assessed the impact of postoperative adjuvant gefitinib on overall survival (OS). Patients with completely r...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of clinical oncology Ročník 31; číslo 27; s. 3320
Hlavní autori:	Goss, Glenwood D, O'Callaghan, Chris, Lorimer, Ian, Tsao, Ming-Sound, Masters, Gregory A, Jett, James, Edelman, Martin J, Lilenbaum, Rogerio, Choy, Hak, Khuri, Fadlo, Pisters, Katherine, Gandara, David, Kernstine, Kemp, Butts, Charles, Noble, Jonathan, Hensing, Thomas A, Rowland, Kendrith, Schiller, Joan, Ding, Keyue, Shepherd, Frances A
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 20.09.2013
Predmet:	Aged Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - surgery Chemotherapy, Adjuvant Disease-Free Survival Double-Blind Method Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - pathology Lung Neoplasms - surgery Male Neoplasm Staging Placebos Prospective Studies Quinazolines - adverse effects Quinazolines - therapeutic use Survival Rate Treatment Outcome
ISSN:	1527-7755, 1527-7755
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!